{
  "ticker": "MDGL",
  "company_name": "Madrigal Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06397872",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Renal Impairment",
      "start_date": "2024-03-06",
      "completion_date": "2024-12-31",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04951219",
      "title": "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Non-Alcoholic Fatty Liver Disease",
      "start_date": "2021-07-09",
      "completion_date": "2026-04",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03900429",
      "title": "A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "NASH - Nonalcoholic Steatohepatitis",
      "start_date": "2019-03-28",
      "completion_date": "2028-01",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04671069",
      "title": "Drug Interaction Study of MGL-3196 With Clopidogrel",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2019-07-26",
      "completion_date": "2019-09-14",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT01367873",
      "title": "Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Drug Safety",
      "start_date": "2011-06",
      "completion_date": "2011-10",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04197479",
      "title": "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Non-Alcoholic Fatty Liver Disease",
      "start_date": "2019-12-16",
      "completion_date": "2023-01-06",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02749578",
      "title": "Drug Interaction Study of MGL-3196 With Atorvastatin",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2016-04",
      "completion_date": "2016-05",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04671056",
      "title": "Drug Interaction Study of MGL-3196 With Pioglitazone",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2018-11-09",
      "completion_date": "2019-01-05",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04643795",
      "title": "Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver",
      "start_date": "2018-10-25",
      "completion_date": "2021-08-04",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03220165",
      "title": "Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2017-08-06",
      "completion_date": "2017-09-03",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 16,
    "by_phase": {
      "PHASE1": 10,
      "PHASE3": 4,
      "PHASE2": 2
    },
    "by_status": {
      "COMPLETED": 13,
      "ACTIVE_NOT_RECRUITING": 3
    },
    "active_trials": 3,
    "completed_trials": 13,
    "conditions": [
      "Drug Safety",
      "Healthy",
      "Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver",
      "Heterozygous Familial Hypercholesterolemia",
      "NASH - Nonalcoholic Steatohepatitis",
      "NASH, Cirrhosis, Liver",
      "Non-Alcoholic Fatty Liver Disease",
      "Non-alcoholic Steatohepatitis",
      "Renal Impairment"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:29.399087",
    "search_query": "Madrigal Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Madrigal+Pharmaceuticals,+Inc."
  }
}